T1	Participants 116 153	sentinel lymph node-positive patients
T2	Participants 446 526	patients with sentinel lymph node-positive (SLN+) primary invasive breast cancer
T3	Participants 884 916	patients with SLN+ breast cancer
T4	Participants 939 979	Patients with SLN+ primary breast cancer
T5	Participants 1287 1304	474 SLN+ patients
T6	Participants 1524 1601	more patients were premenopausal (34% vs. 27%; P = .095) and had pT2-3 tumors
T7	Participants 1706 1825	there were more patients with known human epidermal growth factor receptor type 2 positive tumor (12% vs. 17%, P = .066
